Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCL0037 CS23064 Featured
CS23064 is a cholesterol-containing ionizable lipid for three-component lipid nanoparticles and mRNA vaccine delivery. Its imidazole-containing amino headgroup is connected to a cholesteryl ester and a branched lipid ester, enabling formulation with DOPE and DMG-PEG2000 without a separate cholesterol component. CS23064-based LNP1 supports mRNA expression in Hep3B cells and predominantly local expression after intramuscular administration in mice. SARS-CoV-2 S-protein mRNA vaccination with LNP1 elicits antigen-specific antibody and CD8+ T-cell responses in mice.
More description
DCL0028 HX1 Featured
HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied as a component of lipid nanoparticles (LNPs) for RNA delivery to the central nervous system. In a preclinical study, HX1-containing LNPs supported reporter mRNA expression and functional CRISPR-mediated genome editing in the mouse brain. The researchers also detected luciferase expression in the brain of a non-human primate after delivery of reporter mRNA. In a separate mouse model, HX1-containing LNPs carrying Il10 mRNA reduced markers of inflammation and tissue injury following brain irradiation.
More description
DCC4281 Psb-10129 Featured
Positive modulator of ATP effects at P2X2 receptors
More description
DCL0033 Acuitas Lipid 17 (ALC-0315 retro-ester) Featured
Acuitas Lipid 17 (ALC-0315 retro-ester) is an ester-linked ionizable amino lipid identified as Compound 17 in Acuitas patent WO2017075531A1. It contains a 4-hydroxybutyl tertiary-amine head group and two branched 2-hexyldecyl ester tails, with reversed ester orientation relative to ALC-0315. It is intended for research on lipid nanoparticles and mRNA delivery.
More description
DCL0031 LQ089 Featured
LQ089 is a tertiary-amine ionizable lipid reported in patent CN118506877A for mRNA lipid-nanoparticle research. In the cited luciferase-mRNA formulation, LQ089 LNPs showed higher whole-body reporter-expression exposure than the MC3 comparator after intravenous administration in mice. These preclinical results apply to the reported complete formulation and study conditions.
More description
DCL0032 DPG-PEG 2000 (16:1) Featured
DPG-PEG 2000 (16:1) is a PEGylated lipid with two unsaturated C16 acyl chains and a methoxy-PEG segment. It is used as a PEG-lipid component in lipid-carrier research.
More description
DCL0030 W3 Featured
W3 is a vitamin E-modified, SM-102-derived ionizable lipid studied for mRNA delivery. The published study reports reduced inflammatory responses and intracellular oxidative stress with W3-containing LNPs relative to SM-102 LNPs. An optimized W3 formulation, termed sW3, was investigated for spleen-associated mRNA expression and antitumour vaccination. These preclinical findings apply to the complete formulations and experimental conditions; they do not establish clinical safety or the performance of isolated W3.
More description
DCL0026 OL-56 (HO-PEG-Ste) Featured
OL-56 (HO-PEG-Ste) is a hydroxyl-terminated PEG stearate for research on PEG-lipid components of lipid nanoparticles. It combines a PEG chain with a single C18 fatty-acid anchor through an ester linkage.
More description
DC31692 Fludrocortisone Featured
Fludrocortisone is a synthetic corticosteroid with moderate glucocorticoid potency and much greater mineralocorticoid potency. Therapeutically, it is used for its mineralocorticoid activity and not for its glucocorticoid activity. Fludrocortisone has been used in the treatment of cerebral salt wasting syndrome. However, it is used primarily to replace the missing hormone aldosterone in various forms of adrenal insufficiency such as Addison's disease and the classic salt wasting (21-hydroxylase deficiency) form of congenital adrenal hyperplasia. Due to its effects on increasing Na+ levels, and therefore blood volume, fludrocortisone is the first line of treatment for orthostatic intolerance and postural orthostatic tachycardia syndrome (POTS). It can be used to treat low blood pressure. Fludrocortisone is also used as a confirmation test for diagnosing Conn's syndrome (aldosterone producing-adrenal adenoma).
More description
DC68259 Ki6783 Featured
DC68258 PPARγ agonist-27 Featured
PPARγ agonist-27 is an orally active and blood-brain barrier-penetrant PPARγ agonist with EC50 = 4.7 μM. PPARγ agonist-27 activates PPARγ, upregulates downstream Klotho gene expression, and simultaneously inhibits mitochondrial ROS production. PPARγ agonist-27 can be used in research related to neurological diseases such as Alzheimer's disease.
More description
DC68257 3-((S)-3-aminopiperidin-1-yl)-5-(3,5-dimethylisoxazol-4-yl)-3-phenylindolin-2-one Featured
DC68256 2-(5,9-dimethyl-7-oxo-3-phenyl-7H-furo[3,2-g]chromen-6-yl)acetic acid Featured
DC68255 Lorglumide sodium salt Featured
Lorglumide sodium (CR-1409 sodium) is an orally active Cholecystokinin Receptor antagonist. Lorglumide sodium inhibits pancreatic cancer cell proliferation, induces G0/G1 phase arrest and apoptosis, and downregulates MMP-2. Lorglumide sodium inhibits gastrin-stimulated Ornithine decarboxylase activity and DNA synthesis, and shows low CCKA/CCKB selectivity. Lorglumide sodium blocks Caerulein (HY-A0190)-induced exocrine pancreatic secretion and pancreatic tissue hyperplastic changes in rats, and inhibits gallbladder emptying induced by exogenous and endogenous CCK in mice.
More description
DC68254 N-(2-((1-methylpyrrolidin-3-yl)oxy)pyridin-3-yl)isonicotinamide hydrochloride Featured
DC68253 3-(4-chlorophenyl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione Featured
DC68252 (E)-N-(4-oxocyclohexyl)-3-(3,4,5-trimethoxyphenyl)acrylamide Featured
DC68251 Cinepazide Impurity F Featured
DC68250 N-Desmethyl Zopiclone Hydrochloride Featured
DC68249 4-(3-(1-(4--Cyano-3-(trifluoromethyl)phenyl)methyl-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazolin-7-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile Featured
DC68248 DCN1-IN-2 Featured
DCN1-IN-2 is a DCN1 inhibitor with an IC50 value of 2.96 nM. DCN1-IN-2 can alleviate Ang II/TGFβ-induced activation of cardiac fibroblasts.
More description
DC68247 6a-hydroxy-3-(2-hydroxy-5-methylphenyl)-5-(tetrahydro-2H-pyran-4-yl)-4-(4-(trifluoromethyl)phenyl)-3a,4,5,6a-tetrahydropyrrolo[3,4-c]pyrazol-6(1H)-one Featured
DC68246 N-((8-hydroxyquinolin-7-yl)(p-tolyl)methyl)pentanamide Featured
DC68245 D359-0396 Featured
D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD.
More description
DC68243 Atrazine-desethyl Featured
Atrazine-desethyl is a triazine herbicide.
More description
DC68244 6-(4-isopropylphenyl)-7,9-dimethyl-11-phenyl-6,7-dihydropyrimido[4',5':3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9H)-dione Featured
DC68242 (E)-6-(4-(4-ethylphenyl)but-1-en-1-yl)-2,3-dihydro-1H-inden-1-one Featured
DC71057 Indoramin Featured
Indoramin is an orally active antihypertensive agent. Indoramin is also selective for the α1A-adrenoceptor.
More description
DC43294 PF-429242 dihydrochloride Featured
Novel subtilisin kexin isozyme-1/site-1 (SKI-1/S1P) protease inhibitor
More description
DC10951 MPT0E028 Featured
MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X